Broader equities have been relatively volatile over the past few months. In an environment like this, it's best to prioritize investing in well-established, profitable corporations. While small-cap stocks may have higher upside potential than much larger companies, the risks they entail often make them not worth investing in. With that as a backdrop, let's consider one smaller company that has performed pretty well over the trailing-12-month period, but isn't worth your time: Amarin (AMRN 1.00%). Instead of betting on this small drugmaker, it's best to put your hard-earned money into a pharmaceutical leader like Novartis (NVS 2.98%) instead. Amarin's prospects are bleak Amarin's shares have climbed about 22% over the past year. However, the stock's future looks uncertain at best. While Amarin does have an approved product on the market, Vascepa, a medicine used to reduce the risk of various cardiovascular events, there have been generics of this drug on the market for years. As a result, sales are moving in precisely the wrong direction. In its fiscal 2025, total revenue decreased by 6.5% year over year to $213.6 million. Despite losing patent exclusivity for its sole approved product, Amarin has a plan to improve its business. In fact, it has already made progress along those lines. One of its goals was to cut costs, notably by reducing its workforce. In 2025, Amarin's net loss per share was $0.09, significantly better than the $0.20 reported in 2024. This progress, despite the decreased sales, is noteworthy. Expand NASDAQ : AMRN Amarin Plc Today's Change ( -1.00 %) $ -0.14 Current Price $ 13.79 Key Data Points Market Cap $290M Day's Range $ 13.70 - $ 13.82 52wk Range $ 7.08 - $ 20.90 Volume 2.1K Avg Vol 94K Gross Margin 56.65 % It's also worth noting that Amarin is engaged in a legal battle with generic-drug maker Hikma Pharmaceuticals, claiming that Hikma marketed its generic version of Vascepa in ways that infringed on a still-patented use of the original medici...

georgeclerk/iStock Unreleased via Getty Images Investment Thesis Since my last coverage Pfizer ( PFE ) is up 8% and the stock’s current bull case centers around resilience and reinvention. While the growth rate may not be what investors want to see, the reality is that Pfizer is reinventing its cost structure, improving operating discipline, and focusing on the higher-value therapeutic areas of oncology and specialty. Therefore, Pfizer’s management team has been working diligently to reinvent the business, and that should bode well for the company’s margins and earnings power in the coming years. In my view, Pfizer is moving from the pandemic windfall story to a leaner, more focused biopharma for sustainable, attractive returns. Data by YCharts Why Pfizer’s Operational Discipline Powers Durable Cash Flow and Dividend Strength In my opinion, Pfizer has a high level of operational efficiency that leads to margins well above industry averages. I see this as an operational discipline and bullish element for Pfizer stock. Pfizer has a trailing gross profit margin of 75.81% . This is considerably higher than the sector median of 59.35% and the difference of 27.73% means Pfizer is doing manufacturing and cost control more sharply than the sector. High gross margins means Pfizer retains a large portion of topline after accounting for the cost of sales. This retention drives capital to fund OpEx, research, and capital returns. This operational edge extends beyond gross margins to EBITDA. Pfizer has a TTM EBITDA Margin of 41.05% and the sector median sits at 10.40%. Pfizer outperforms the sector by 295% here on this metric. This wide gap means Pfizer controls operating costs relative to revenue. Pfizer converts sales into earnings in a way that protects cash flows even when top-line revenue faces pressure. The TTM EBIT Margin further confirms this trend. Pfizer hit an EBIT Margin of 30.62% that exceeds the sector median of 5.51% by 455.47%. These margin premiums means Pfizer ...

As fears of the conflict between the U.S. and Iran took deeper root Tuesday, Nvidia stock tumbled, falling close to a key level. Is Nvidia stock a buy or sell now? The stock did not get a positive reaction to earnings though the company exceeded expectations as posted by FactSet.

文章提及标的 美元指数 -- 彭博美元指数上涨1%，创2025年5月以来最大涨幅。

Pedestrians make their way early morning in the hallway of the Grand Central terminal in New York on February 29, 2024. Charly Triballeau | AFP | Getty Images More than 4 in 10 people — or 43% — are trying to change their career fields this year, according to a new report by online employment platform FlexJobs. Concern around possible layoffs , the role of artificial intelligence and work-life balance are all factors driving people to want to move to a new profession, said Keith Spencer, career expert at FlexJobs. The survey, conducted in early February, included over 4,000 U.S. respondents. But changing careers can feel daunting, and data show that most people are still reluctant to leave their current employers. "Many people know they want to leave their current job, but haven't fully defined the role they want or how their existing skills translate to a new field," Spencer said. "Without that understanding, it's easy to lose confidence and motivation." 'The collapse of linear career paths' The old formula for a successful career — "pick a track, work hard and follow it upward" — isn't working for many people anymore, said executive coach Megan Hellerer. "The advent of AI has accelerated the collapse of linear career paths," Hellerer said. "When certainty and safety disappear, people start asking deeper questions: If the ladder isn't secure, do I even want to be climbing it?" Read more CNBC personal finance coverage AI, layoffs spur workers to want a career change, survey finds — but few may do it Poor coordination can cost couples an average $14,000 in retirement wealth Gold price jumps on Middle East turmoil. What to know before investing What student loan borrowers need to know about judge's ruling on SAVE plan As Iran strikes disrupt flights, why travel insurance may fall short How the U.S.-Iran war could impact gas prices at the pump More low- and middle-income Americans are investing, report finds. Here's why Average IRS tax refund is up 10.2%, based on earl...

全國人大常委李慧琼出席港澳辦座談交流後，引述港澳辦主任夏寶龍指，香港擁有優越條件，在「十五五」時期，必定大有作為，亦要更好地融入及服務國家發展大局。 全國人大常委李慧琼稱：「今次夏主任講話的主題是齊心協力、團結奮鬥，抓緊『十五五』規劃機遇，將香港及澳門發展得更好，更好發揮香港及澳門的角色，融入及服務國家發展大局。我相信全體人大代表，都會好好學習夏主任今天講話精神，亦會將這番講話精神，貫徹在開會過程中，回到香港亦會宣傳好，在北京開會的內容，令社會各界更掌握『十五五』規劃綱要。」

FCC主席布伦丹·卡尔周二告诉媒体，派拉蒙收购 华纳 兄弟探索公司的要约是一笔“好交易”，将“迅速”获得批准。卡尔表示，之前 Netflix 的竞标会“引发很多竞争担忧”。 派拉蒙表示，如果交易未获监管批准，将支付70亿美元的分手费。 FCC主席布伦丹·卡尔告诉媒体，派拉蒙收购华纳兄弟探索公司的竞标比Netflix的“更干净”，并补充说，他预计该交易将“相当快”获得批准。 卡尔周二在巴塞罗那世界移动通信大会间隙表示：“当Netflix是潜在买家时，存在很多担忧。”“那种特定的组合引发了很多竞争担忧。” 派拉蒙Skydance上周提交了修订后的要约，以每股31美元的价格收购WBD的全部股份，高于之前的每股30美元，WBD董事会认为这优于Netflix现有的提案。 Netflix原计划以每股27.75美元的价格收购这家媒体巨头的制片厂和流媒体业务，但表示鉴于派拉蒙的报价，这“在财务上不再具有吸引力”。 该合并交易尚需要获得监管机构的批准。 卡尔称，Netflix获得监管批准“将是一条非常艰难的道路”，并补充说派拉蒙的交易“干净得多，根本没有引起同样类型的担忧。” 他补充说：“我认为从中可以产生一些真正的消费者利益。” 这两笔交易都引发了围绕美国影院行业的反垄断问题，引发了对好莱坞潜在失业或电影数量减少的担忧。Netflix的拟议合并也引发了关于流媒体主导地位的问题，因为它将Netflix和WBD的HBO Max这两个最受欢迎的流媒体服务结合在一起。 周一，派拉蒙表示计划每年至少发行30部电影，即每个制片厂15部。高管们还表示，交易完成后，将把其流媒体服务Paramount+与HBO Max合并为一项服务。 目前尚不清楚派拉蒙和WBD的监管程序将涉及哪些内容。FCC通常会审查涉及全国广播公司之一的交易，包括派拉蒙的CBS，并于去年支持了派拉蒙与Skydance的合并。 卡尔补充说：“即使FCC有任何角色，那也是相当小的角色。我认为这是一笔好交易，我认为它应该很快通过。” 与Netflix的拟议交易不同，派拉蒙的竞标涵盖了WBD的付费电视网络，如CNN、TBS和TNT。 如果交易未获监管批准，派拉蒙已提出支付70亿美元的分手费。它已经支付了WBD因交易取消而欠Netflix的28亿美元分手费。 “容易得多” 围绕Netflix-WBD交易的一些担忧包括消费者价格上涨和竞争减...

Apple on Tuesday announced a new MacBook Pro and MacBook Air, both powered by its latest chips, as well as a new family of displays. The latter includes a new $1,599 Studio Display and a $3,299 Studio Display XDR. The new 27-inch displays come with better cameras and improved connectivity. Both displays feature a 12MP Center Stage camera, which the company says, offers improved image quality. There’s also support for Desk View, a feature that shows your face and an overhead view of your desk at the same time. The Studio Display’s 5K Retina display has over 14 million pixels, 600 nits of brightness, and supports the P3 wide-gamut color standard that covers a broader range of the visible color spectrum than standards like sRGB. Image Credits:Apple The displays come with Thunderbolt 5 ports, so they can be connected to accessories and be used to daisy-chain up to four displays (a Thunderbolt 5 Pro cable comes included). There’s also a three-microphone array and a six-speaker sound system with Spatial Audio. Apple says the new sound system offers 30% deeper bass than the last generation. The higher-end Studio Display XDR features a 5K Retina XDR display (5120×2880 resolution) that has a mini-LED backlight and more than 2,000 local dimming zones. It can go up to 1000 nits of SDR brightness and 2000 nits of peak HDR brightness, and has a 1,000,000:1 contrast ratio. It also supports the Adobe RGB color standard. The display has a refresh rate of 120Hz, supports Adaptive Sync, and comes with DICOM medical imaging presets and a Medical Imaging Calibrator, which make it usable in medical settings. Apple says the Medical Imaging Calibrator on macOS is pending FDA clearance and is expected to be available soon in the U.S. Techcrunch event Disrupt 2026: The tech ecosystem, all in one room Your next round. Your next hire. Your next breakout opportunity. Find it at TechCrunch Disrupt 2026, where 10,000+ founders, investors, and tech leaders gather for three days of 250+ tactical s...

佑駕創新(02431.HK)與寧德時代(03750.HK)簽署戰略合作 AASTOCKS.com

This Stock Market Selloff’s Biggest Fallers All Have One Thing in Common Barron's

Sandisk, Micron, Corning. This Stock Market Selloff's Biggest Fallers Have One Thing in Common. Barron's

佑駕創新(02431.HK)與寧德時代(03750.HK)簽署戰略合作財經新聞Financial News AASTOCKS.com

佑駕創新(02431.HK)與寧德時代(03750.HK)簽署戰略合作- 財經新聞Financial News AASTOCKS.com

Target Corporation (NYSE:TGT) delivered a meaningful earnings beat this morning, reporting fourth quarter adjusted EPS of $2.44, surpassing the Yahoo Finance consensus estimate of $2.16 by approximately 13.0%. The beat is notable given management’s emphasis on disciplined cost control, with GAAP EPS at $2.30 including $0.15 of non-recurring business transformation costs. Q4 Fiscal 2025 Earnings ... Target’s $4.48B Free Cash Flow Strengthens Dividend Case

《科创板日报》3月3日讯（记者 郭辉） 佰维存储今日（3月3日）发布2026年1-2月业绩预告的自愿披露公告。 公告显示，经财务部门初步测算，佰维存储预计2026年1月-2月实现营业收入40亿元至45亿元，与上年同期相比，将增加30.91亿元至35.91亿元，同比增长340%至395%。 佰维存储预计，2026年1月-2月实现归母净利润15亿元至18亿元，与上年同期相比，将同比增加921.77%至1086.13%。 关于业绩变化原因， 佰维存储表示，2026年存储行业迎来高度景气周期，AI算力与产业国产化驱动DRAM/NAND价格持续上涨，行业供不应求，公司受益显著。同时，为提高公司产品在AI时代的市场竞争力，佰维存储持续加大芯片设计、解决方案、先进封测及测试设备等领域的投入力度。 佰维存储在近日发布的2025年度业绩快报则显示，2025全年实现营收112.96亿元，同比增长68.72%；实现归母净利润8.67亿元，同比增长437.56%。 佰维存储在今年1月接受机构调研时表示，存储产品价格在2026年第一季度、第二季度有望持续上涨。在供应方面，该公司积极备货，目前库存较为充足。 据称，佰维存储已与全球主要存储晶圆原厂继续签订LTA（长期供应协议），该公司北美客户亦积极与原厂沟通，帮助公司锁定原厂产能，有效保障关键原材料的稳定供应。 产品方面，佰维存储预计2026年AI眼镜等高价值AI端侧产品将持续放量。 据悉，佰维存储ePOP存储产品已进入Meta、Rokid、雷鸟创新等AI眼镜厂商，以及Google、小天才、小米等智能穿戴厂商供应链体系。2025年佰维存储AI新兴端侧存储产品收入约17.51亿元，其中，AI眼镜存储产品收入约9.6亿元。 佰维存储晶圆级先进封测制造项目正积极投入建设。据佰维存储称，其位于东莞松山湖的晶圆级先进封测制造项目整体进展顺利，正按照客户需求推进打样和验证工作，预计2026年底晶圆级先进封测制造项目月产能将达到5000片，预计2027年底月产能将达到1万片，并预计将于2026年年底开始贡献收入。 佰维存储还在接受机构调研时透露，该公司已构建覆盖Bumping、Fan-in、Fan-out、RDL等晶圆级先进封装技术，主要规划两大类产品线，分别是应用于先进存储芯片的FOMS系列，以及先进存算合封CMC系列。 目前其先进封装良率已达95%以上，...

Steve Borthwick has wielded the axe and made 12 changes to his England team to face Italy, picking an entirely different back line as he seeks to salvage his side’s Six Nations campaign with the most radical selection of his tenure. Borthwick has made nine personnel changes as well as moving Tommy Freeman to outside-centre, Ben Earl back to No 8 and Tom Curry to openside. Fin Smith has also been installed at fly-half and with Henry Pollock dropped after just one start. Seb Atkinson, Cadan Murley, Guy Pepper and Elliot Daly all come into the side to make their first appearances of this year’s Six Nations. In a measure of just how radical Borthwick’s selection is, only the captain Maro Itoje and the props Ellis Genge and Joe Heyes are selected in the same position as against Ireland. In the pack, Jamie George comes in for Luke Cowan-Dickie at hooker, Pepper returns to the side with Pollock returning to the bench and Alex Coles starts in the second row alongside Itoje. Ollie Chessum, who has arguably been England’s most effective player in the championship, is among the replacements after he sat out training on Monday. On the back of dismal defeats by Scotland and Ireland, Borthwick has rolled the dice. George Ford, Fraser Dingwall, Henry Arundell and Freddie Steward drop out of the matchday 23 entirely while Alex Mitchell’s injury absence means Ben Spencer starts at scrum-half. At fly-half, Smith is named for only his second start since last year’s Six Nations despite sitting out training on Monday due to illness while Gloucester’s Atkinson is set for his Twickenham bow at inside-centre, having made his debut on last summer’s tour of Argentina. View image in fullscreen Ben Spencer (left) and Guy Pepper are among the new faces in the England XV. Photograph: Adam Davy/PA Smith and Atkinson have not played together for England before but both were at Worcester before the club went bust in 2022. Outside them, Freeman comes back to outside-centre in place of the injured Ol...

《科创板日报》3月3日讯（记者 史士云） 今日晚间，艾力斯（688578.SH）披露2026年第一季度业绩预告，成为2026年科创板首家发布一季度业绩预告的生物医药公司。 根据公告，经初步测算， 艾力斯今年第一季度实现营收入15.5亿元，较上年同期增加约4.52亿元，同比增长41.12%，归母净利润为5.9亿元，比上年同期增加约1.80亿元，同比增长43.73% 。 对于业绩的增长，艾力斯称受益于国家医保政策的支持与覆盖，公司商业化产品销售收入及推广服务收入持续增长，进而推动了经营业绩的继续攀升。 作为一家专注于肿瘤领域的创新药企，艾力斯自主研发的第三代EGFR‑TKI药物伏美替尼为其核心当家品种，在营收结构中占据绝对的主导地位，为公司贡献了97%以上的营业收入。 2021年3月，伏美替尼首次获得国家药监局批准上市，截至目前，其用于EGFR敏感突变非小细胞肺癌一线治疗适应症和二线治疗适应症均已被纳入国家医保目录。今年2月，伏美替尼又获批用于二线治疗经检测确认存在EGFR20外显子插入突变的局部晚期或转移性NSCLC成人患者。 伏美替尼堪称“医保红利”的典型受益者， 其在上市首年便突破2亿元，在2021年底被纳入国家医保目录后，销售业绩更是一路走高。 财务数据显示，2021-2024年，伏美替尼销售收入分别为2.36亿元、7.90亿元、19.78亿元、35.06 亿元。根据艾力斯医药2025年业绩快报披露的51.71亿元总营收推算，伏美替尼2025年销售额或已逼近50亿元，以此计算，伏美替尼自上市以来的累计销售收入已超100亿元。 但值得注意到，近年来，伏美替尼营收增速已明显放缓，2022年-2024年，其增速分别为234.75%、150.38%、77.25%。 也正是依托伏美替尼的亮眼业绩，艾力斯的净利润也在连年大增，2021年-2025年，其净利润分别为0.18亿元、1.31亿元、6.44亿元、14.30亿元、21.81亿元。 不过，在伏美替尼所处的第三代EGFR-TKI领域，竞争已变得颇为激烈。 《科创板日报》注意到，截止目前，国内已有8款第三代EGFR-TKI上市，除了伏美替尼，其他7款分别是阿斯利康的奥希替尼、翰森制药的阿美替尼、贝达药业/益方生物的贝福替尼、倍而达药业的瑞齐替尼、圣和药业的瑞厄替尼、奥赛康药业的利厄替尼、以及强生的兰泽替尼。 问题也随之而来...

Image source: The Motley Fool. Tuesday, March 3, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Frank D’Orazio Chief Financial Officer — Sarah Doran Operator Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Net Income -- $47.4 million for the year, up from a net loss of $81.1 million in 2024. -- $47.4 million for the year, up from a net loss of $81.1 million in 2024. Net Income to Common Shareholders -- $39.6 million for the year. -- $39.6 million for the year. Operating Earnings -- $54.1 million for the year, or $0.79 per diluted share. -- $54.1 million for the year, or $0.79 per diluted share. Combined Ratio -- 96.6% for the year, improved from 117.6% in 2024. -- 96.6% for the year, improved from 117.6% in 2024. Annualized Adjusted Net Operating Return on Tangible Common Equity -- 15.3% for the year. -- 15.3% for the year. Tangible Common Book Value per Share -- Increased 34% to $8.94. -- Increased 34% to $8.94. Fourth Quarter Operating Earnings -- $16 million, compared to a loss of $40.8 million in the prior year quarter. -- $16 million, compared to a loss of $40.8 million in the prior year quarter. Fourth Quarter Annualized Return on Tangible Common Equity -- 16.2%. -- 16.2%. Expense Ratio -- 30.2% for the year, down more than one point from 2024, with quarterly expense ratio down over 2.5 points from Q1. -- 30.2% for the year, down more than one point from 2024, with quarterly expense ratio down over 2.5 points from Q1. Total Employees -- Ended 2025 with 578 employees, a reduction of over 60 from the beginning of the year. -- Ended 2025 with 578 employees, a reduction of over 60 from the beginning of the year. Gross Written Premium -- Down about 5% for the year, with Property down 27% and Manufacturers and Contractors down 11%. -- Down about 5% for the year, with Property down 27% and Manufacturers and Contractors down 11%. Average Policy Size -- Decreased 9.6% in Q4 and 8.4% for the year, supporting the company’s str...

伊朗德黑兰东北部再次发生多起爆炸 2026-03-03 22:47:36 来源： 同花顺7x24快讯 分享 总台记者当地时间3月3日获悉，伊朗首都德黑兰东北部地区再次发生多起爆炸。该爆炸点距离总台报道点办公室500米左右。(央视新闻)

Image source: The Motley Fool. Tuesday, March 3, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — David Hallal President and Head of Research & Development — Akshay K. Vaishnaw Chief Operating Officer — R. Keith Woods Chief Financial Officer — Vikas Sinha Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Cash and Cash Equivalents -- $368 million at year-end, including $60.4 million from warrant exercises completed by December 31. -- $368 million at year-end, including $60.4 million from warrant exercises completed by December 31. Debt Facility -- Newly secured $550 million facility with Blue Owl Capital, consisting of $100 million drawn to refinance prior debt, $100 million available and expected to be drawn in Q1, further $150 million accessible post-FDA approval, and an incremental $200 million subject to mutual consent. -- Newly secured $550 million facility with Blue Owl Capital, consisting of $100 million drawn to refinance prior debt, $100 million available and expected to be drawn in Q1, further $150 million accessible post-FDA approval, and an incremental $200 million subject to mutual consent. Operating Expenses -- $384.6 million for the year, with $75.6 million as noncash stock-based compensation; fourth-quarter expenses totaled $91.9 million with $19.4 million stock-based compensation. -- $384.6 million for the year, with $75.6 million as noncash stock-based compensation; fourth-quarter expenses totaled $91.9 million with $19.4 million stock-based compensation. BLA Resubmission and U.S. Approval Guidance -- Management reaffirmed expectations to resubmit the upitigramab BLA and launch in the U.S. pending approval in 2026. -- Management reaffirmed expectations to resubmit the upitigramab BLA and launch in the U.S. pending approval in 2026. FDA Catalent Site Reinspection Status -- FDA completed a field visit to the Catalent, Indiana facility following resumed manufacturing activities and expressed no additional reques...

TLDR Analysts hold a StrongBuy consensus on NVDA with a 12-month average price target of $271.11 Morgan Stanley reinstated Nvidia as its top semiconductor pick, with a $260 price target and Overweight rating UBS analyst Timothy Arcuri reiterated a Buy rating on March 2 with a $245 price target Nvidia posted 65% revenue growth over the past 12 months, reaching $216 billion, with a 60.4% operating margin The company’s GTC conference runs March 16–19, where investors expect updates on product timelines and AI demand 💥 Find the Next KnockoutStock! Get live prices, charts, and KO Scores from KnockoutStocks.com , the data-driven platform ranking every stock by quality and breakout potential. Nvidia has had a rough week on paper — down 5.4% over the past seven days — but Wall Street isn’t blinking. NVIDIA Corporation, NVDA The stock closed at $182.48, still up 60% over the past year. Analysts remain firmly bullish, pointing to strong fundamentals and a packed pipeline of AI-driven demand. Trefis has set a price target of $236, citing Nvidia’s financial health and operating performance. The firm rates the stock as “Attractive but Volatile,” flagging its very high valuation as the main caveat. On the revenue side, Nvidia grew its top line 65% over the past 12 months, from $130 billion to $216 billion. Quarterly revenues hit $68 billion in the most recent quarter, up 73.2% year-over-year. The company’s three-year average revenue growth rate sits at 101.8%, one of the strongest in the market. Profitability is equally striking. Operating income for the last 12 months came in at $130 billion, representing a 60.4% operating margin. Net income reached roughly $120 billion, good for a 55.6% net margin. Operating cash flow was nearly $103 billion, with a cash flow margin of 47.6%. Nvidia holds $63 billion in cash against $11 billion in debt — a debt-to-equity ratio of just 0.3%. Analyst Backing UBS analyst Timothy Arcuri reiterated his Buy rating on March 2 with a $245 price target....

When the new Formula One season begins on Sunday in the usual fever of excitement and anticipation, consider amid the maelstrom the Cadillac team. Before the lights go out in Melbourne, F1’s newest entrant will have a deserved chance to take a breath and savour for but a moment, their remarkable achievement of simply having made it to the grid. The US team backed by General Motors has been built, aside from those involved in the pre-planning, from scratch in what will be a year and a day since its entry was formally approved. As their team principal, Graeme Lowdon, explained, that process had begun in an empty room with a screwdriver and an A4 sheet of paper. While Audi are also new entrants, they have taken over the extant Sauber team; Cadillac are the first new constructor to enter as a startup since Haas joined a decade ago. Drivers Valtteri Bottas and Sergio Pérez will be the veterans at the sharp end and Bottas, a 10-time race winner who competed alongside Lewis Hamilton at Mercedes when the team were the benchmark in F1, is well placed to appreciate what Cadillac have pulled off. “Everyone has worked their ass off the last months,” he says. “For us to do our shakedown in January in Silverstone that was for me a miracle. When you put that in perspective, what an achievement for a team from a standing start. “It’s difficult to explain how many hundreds of people you need. How many thousands of pieces you need to first design and then manufacture. There are so many things in the car that can go wrong. It’s just so much work from everyone to get here. It’s really important to try to put that across, because people just hear: ‘Oh, it’s a new team’ and assume that was a relatively simple thing.” Since they were given the provisional go ahead at the Las Vegas GP in 2024, the team, who will use Ferrari engines until 2029 when General Motors will produce the first of their own power units, have been building at a ferocious rate on every level. The personnel numbers are...

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo

苹果 在致力于升级Siri的过程中，可能会将其与 谷歌 的合作关系推进一步。有报道称，双方合作可能不仅限于人工智能模型，还可能延伸至云基础设施。 在确认计划利用谷歌的人工智能技术开发下一版本Siri之后，据悉苹果正在探索谷歌云能否在幕后为升级版助手的部分功能提供支持。据报道，谷歌已评估在其自有数据中心设置服务器以支持这项工作，同时同意遵守苹果严格的隐私要求。 谷歌云已在某些领域与苹果合作，包括存储服务和训练苹果部分内部人工智能模型。苹果似乎并不打算大幅扩展自身的数据中心规模，而是倾向于采取一种混合策略，将其私有云与谷歌和 亚马逊 云服务等外部供应商结合起来。 责任编辑：张俊 SF065

Ayar Labs, a chip technology startup backed by Nvidia, has raised a fresh $500 million of funding to accelerate production of its optical chip technology, underlining continued investor appetite for infrastructure powering artificial intelligence. The California-based company said the Series...

Nvidia Earnings to Include Cost of Stock-Based Pay. That’s Bad News for Broadcom, AMD. Barron's

Image source: The Motley Fool. Tuesday, March 3, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President & Chief Executive Officer — John F. Kasel Executive Vice President & Chief Financial Officer — William M. Thalman Vice President, Corporate Development, Investor Relations, & Treasurer — Lisa M. Gordon TAKEAWAYS Revenue -- $160.4 million, up 25.1%, marking the highest fourth quarter sales since 2018. -- $160.4 million, up 25.1%, marking the highest fourth quarter sales since 2018. Gross Profit -- Up 10.6%, with gross margin at 19.7%, a decline of 260 basis points due to weaker Rail margins, primarily from the TS& S UK business. -- Up 10.6%, with gross margin at 19.7%, a decline of 260 basis points due to weaker Rail margins, primarily from the TS& S UK business. SG&A Expense -- Down $1.3 million, or 5.2%, with SG&A as a percentage of sales improved by 470 basis points to 14.4%. -- Down $1.3 million, or 5.2%, with SG&A as a percentage of sales improved by 470 basis points to 14.4%. Adjusted EBITDA -- $13.7 million, an 89% increase driven by higher gross profit and lower SG&A expenses. -- $13.7 million, an 89% increase driven by higher gross profit and lower SG&A expenses. Operating Cash Flow -- $22.2 million in Q4, bolstering liquidity for capital deployment and debt reduction. -- $22.2 million in Q4, bolstering liquidity for capital deployment and debt reduction. Net Debt -- Reduced by $16.9 million, ending at $38.4 million. -- Reduced by $16.9 million, ending at $38.4 million. Gross Leverage Ratio -- Improved to 1.0x from 1.6x at the quarter’s start. -- Improved to 1.0x from 1.6x at the quarter’s start. Rail Segment Revenue -- $98.0 million, up 23.7%, with Friction Management and Rail Products rising 41.6% and 31.1%, respectively. -- $98.0 million, up 23.7%, with Friction Management and Rail Products rising 41.6% and 31.1%, respectively. Rail Segment Margin -- 17.8%, down 440 basis points, impacted by UK restructuring costs ($1.0 million), higher costs, and unfavorable...

文章提及标的 伦敦金 -- 现货黄金失守5060美元/盎司，日内跌4.93%。

England have shredded their backline and made a total of 12 changes - nine personnel switches and three positional shifts - to their starting line-up to face Italy in the hope a selection revolution will jump-start their stalled Six Nations campaign. Fin Smith starts at fly-half, while Gloucester centre Seb Atkinson comes in at 12 for his third cap, and George Ford and Fraser Dingwall - crucial parts of England's all-conquering autumn campaign - are both left out of the matchday squad entirely. Henry Arundell also loses his place, with Harlequins' Cadan Murley and Sale's Tom Roebuck preferred on the wing, while Elliot Daly comes in for full-back Freddie Steward, who was replaced before half-time in the 42-21 defeat by Ireland last time out. With Ollie Lawrence injured, Tommy Freeman shifts to outside centre from the wing, and Ben Spencer is preferred to Jack van Poortvliet at scrum-half as first-choice Alex Mitchell misses the rest of the tournament with a hamstring problem. That raft of changes - the most England have made to a line-up between Six Nations matches since the tournament expanded in 2000 - means not one of the backline positions is filled by the same player as against Ireland 10 days ago.

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo